the recent expanded fda approval of cilta-cel and ide-cel into earlier lines of myeloma treatment
Published 2 months ago • 61 plays • Length 0:36Download video MP4
Download video MP3
Similar videos
-
1:00
the recent fda approval of teclistamab for r/r multiple myeloma
-
0:45
fda approval of teclistamab for r/r multiple myeloma and the value of immunotherapies
-
1:59
the growing importance of celmods in the treatment of r/r multiple myeloma
-
1:26
mrd in myeloma: the fda perspective
-
4:18
recent advances in the clinical management of myeloma
-
4:04
the future of myeloma treatment and the possibility of cure
-
10:11
monumental-1: talquetamab in r/r multiple myeloma
-
7:31
clinical trial: darzalex (daratumamab) with revlimid/velcade/dex for newly diagnosed myeloma
-
1:53
the future of multiple myeloma treatment
-
3:17
teclistamab in relapsed/refractory multiple myeloma
-
1:30
real-world treatment patterns in third-line therapy for r/r myeloma
-
4:45
a first-in-human trial of regn5458 in r/r myeloma: updated phase i data
-
2:17
extended follow-up of the master trial
-
1:46
changes in the myeloma treatment paradigm
-
2:41
an overview of the latest advances in hematology
-
1:56
treatment selection & sequencing in patients with relapsed, intolerant, or refractory myeloma
-
1:25
safety and efficacy of linvoseltamab for patients with r/r multiple myeloma
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma
-
0:52
mrd for multiple myeloma: is it ready for prime-time?
-
2:09
the candor trial extended follow-up: daratumumab for r/r myeloma
-
1:47
treatment options for penta-refractory multiple myeloma
-
5:46
a review of the treatment evolution in relapsed/refractory multiple myeloma